Dyne Therapeutics, Inc.
Dyne Therapeutics director Jason P. Rhodes sold about $65.2M of DYN common stock on Aug. 13-14, 2026 under a Rule 10b5-1 plan. Prices ranged from $25.00 to $26.20. The sales follow FDA acceptance of Dyne’s zeleciment rostudirsen BLA for Priority Review (target Jan. 21, 2027) and a $375M public offering priced at $20.50.
Rhodes Jason P sold 2,586,928 indirectly-held shares of Dyne Therapeutics, Inc. (DYN) at an average of $25.20 ($25.00–$26.20, $65.18M total) across 6 trades over 2026-08-13 to 2026-08-14 under a Rule 10b5-1 trading plan.
Dyne Therapeutics (DYN) reported a wider Q2 net loss of $178.56 million, or $1.08 per share, and said the FDA cleared its DYNE-302 Phase 1 trial for facioscapulohumeral muscular dystrophy. The company frames DYNE-302 as its third FORCE platform program, adding near-term clinical catalysts amid ongoing cash burn and R&D risk.
Over the past 7 days, alphai's AI scored 2 news stories mentioning DYN (Dyne Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent DYN coverage spans earnings, insider activity and corporate actions.
In the last 30 days, DYN insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($72.1M). The most active reporter was Rhodes Jason P with 6 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider selling via a 10b5-1 plan is typically less bearish than discretionary sales, but it can still pressure sentiment near highs.
The filing is a large insider sale, but it is explicitly under a pre-arranged 10b5-1 plan, which typically reduces signal strength versus discretionary selling.
FDA clearance is a near-term catalyst that can improve probability-weighted timelines, but it also increases R&D intensity and execution risk.
Regulatory progress is framed as lifting pipeline expectations, but the piece emphasizes ongoing losses and dilution risk alongside a DCF-based valuation gap.
The earnings miss plus a large upsized stock offering signals near-term dilution risk while funding extends the runway into 2Q28.
alphai scores every news story that mentions DYN with an AI model for sentiment and relevance, and aggregates insider trades from Dyne Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Dyne Therapeutics director Jason P. Rhodes sold about $65.2M of DYN common stock on Aug. 13-14, 2026 under a Rule 10b5-1 plan. Prices ranged from $25.00 to $26.20. The sales follow FDA acceptance of Dyne’s zeleciment rostudirsen BLA for Priority Review (target Jan. 21, 2027) and a $375M public offering priced at $20.50.
3 min readRhodes Jason P sold 2,586,928 indirectly-held shares of Dyne Therapeutics, Inc. (DYN) at an average of $25.20 ($25.00–$26.20, $65.18M total) across 6 trades over 2026-08-13 to 2026-08-14 under a Rule 10b5-1 trading plan.
2 min readDyne Therapeutics (DYN) reported a wider Q2 net loss of $178.56 million, or $1.08 per share, and said the FDA cleared its DYNE-302 Phase 1 trial for facioscapulohumeral muscular dystrophy. The company frames DYNE-302 as its third FORCE platform program, adding near-term clinical catalysts amid ongoing cash burn and R&D risk.
5 min readSimply Wall St reports Dyne Therapeutics (DYN) received FDA milestones, including clearance to start a Phase 1 trial for DYNE-302 and Priority Review for Duchenne candidate DYNE-251. The stock trades at $25.18 after a 15.56% 30-day gain. A DCF model estimates fair value at $40.88, about 38.4% higher, despite $519.41m losses and no meaningful revenue.
6 min readDyne Therapeutics (DYN) reported Q2 2026 EPS loss of $(1.08), versus a $(0.75) estimate, widening losses 11.34% from $(0.97) a year earlier. Operating expenses rose to $181.7M, driven by R&D of $152.2M and higher G&A. Cash was $898.5M; it priced an upsized $431M offering at $20.50 and expects runway into Q2 2028.
6 min readDyne Therapeutics (Nasdaq: DYN) reported Q2 2026 results and updates. The FDA accepted its BLA for z-rostudirsen (exon 51 DMD) with Priority Review, PDUFA Jan 21, 2027. Dyne completed enrollment of 71 patients in ACHIEVE z-basivarsen REC, topline planned Q1 2027, and received IND clearance for DYNE-302 in FSHD. Cash $898.5M at June 30, 2026; expects funding into Q2 2028.
6 min readDyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dyn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA t
6 min readKersten Dirk sold 261,460 indirectly-held shares of Dyne Therapeutics, Inc. (DYN) at an average of $25.51 ($25.50–$26.04, $6.67M total) across 2 trades on 2026-07-27 under a Rule 10b5-1 trading plan.
2 min readDyne Therapeutics (DYN) said the FDA cleared its IND to start a Phase 1 trial of DYNE-302 for facioscapulohumeral muscular dystrophy (FSHD). The study will assess safety and tolerability in a randomized, placebo-controlled, double-blind multiple ascending dose design, with PK/PD and DUX4 transcriptome and biomarkers. DYN stock was $25.37.
4 min readBiotech and healthcare stocks hit 52-week highs on July 27, 2026. Dyne Therapeutics (DYN) rose over 5% to $26.12 after FDA accepted its Z-Rostudirsen BLA; it raised $431m. Sonida Senior Living (SNDA) reached $44.38 after its CHP acquisition. Silence Therapeutics (SLN) hit $12.19. Amylyx (AMLX) rose to $19.60. Labcorp (LH) climbed to $301.7 after launching a genetic testing platform; Q1 revenue was $3.54b and 2026 revenue guidance $14.65b-$14.80b.
5 min read
